Latest Thrombocytopenia Stories
Approval expands use in treatment of rare type of leukemia SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new indication for Tasigna (nilotinib) for the treatment of a rare blood cancer when it is first diagnosed.
Readers are referred to the cautionary notes regarding Forward-looking information at the end of this release Listed TSX, Symbol: CNJ TORONTO and WINNIPEG, April 20 /PRNewswire-FirstCall/ - Cangene Corporation today reports that it has signed a new agreement with Baxter Healthcare Corporation under which Cangene assumes the commercialization rights to WinRho(R) SDF (Rho(D) Immune Globulin Intravenous (Human)) for the U.S.
KING OF PRUSSIA, Pa., April 19 /PRNewswire/ -- CSL Behring announced today that the U.S.
RESEARCH TRIANGLE PARK, N.C., April 12 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics, Inc., today announced results of a new survey showing that GamunexÂ® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference.
Physicians may be able to safely lower the platelet dosage in transfusions for cancer and bone-marrow transplant patients without risking increased bleeding
WOODCLIFF LAKE, N.J., Jan. 6 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company, AkaRx, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from its first Phase 1/2 study evaluating the safety and efficacy of NplateÂ® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).
NEW ORLEANS, Dec. 6 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced results from three studies on the safety and efficacy of NplateÂ® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).
THOUSAND OAKS, Calif., Nov. 30 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced that it will present updated long-term safety and efficacy data for NplateÂ® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall Pipeline and for Best New Drug for NplateÂ® (romiplostim), at a Nov. 18 ceremony in London.